Johnson & Johnson: Pulmonary Arterial Hypertension trials

The registry lists 60 Pulmonary Arterial Hypertension studies with Johnson & Johnson as lead sponsor. 2 are open to participants now and 33 have results posted.

Phase 1 2Phase 2 4Phase 3 31Phase 4 11No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in KoreaNot yet recruitingNCT07890285
• A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingNCT05179876Phase 3
• A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial HypertensionCompletedNCT05167825Phase 3Results posted
• A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance ImagingTerminatedNCT04435782Phase 4Results posted
• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT03904693Phase 3Results posted
• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActive, not recruitingNCT03492177Phase 2Results posted
• Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial HypertensionCompletedNCT03187678Phase 3Results posted
• Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.CompletedNCT03078907Phase 4Results posted
• A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)CompletedNCT02932410Phase 3Results posted
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionCompletedNCT02558231Phase 3Results posted
• Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial HypertensionCompletedNCT02471183Phase 3Results posted
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtensionCompletedNCT02310672Phase 4Results posted
• A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and SpainTerminatedNCT02081690Phase 3Results posted
• Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT InstrumentTerminatedNCT01847014Phase 3Results posted
• Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT InstrumentCompletedNCT01841762Phase 3Results posted
• Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger SyndromeCompletedNCT01743001Phase 3Results posted
• Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger SyndromeTerminatedNCT01739400Phase 3Results posted
• Epoprostenol for Injection in Patients With Pulmonary Arterial HypertensionCompletedNCT01470144Phase 3Results posted
• Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial HypertensionCompletedNCT01431716Phase 3Results posted
• FUTURE 3 Study ExtensionCompletedNCT01338415Phase 3Results posted
• Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial HypertensionCompletedNCT01223352Phase 3Results posted
• ACT-293987 in Pulmonary Arterial HypertensionCompletedNCT01112306Phase 3Results posted
• Selexipag (ACT-293987) in Pulmonary Arterial HypertensionCompletedNCT01106014Phase 3Results posted
• Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401CompletedNCT01105117Phase 4Results posted
• Epoprostenol for Injection in Pulmonary Arterial HypertensionCompletedNCT01105091Phase 4Results posted
• Iloprost Power Disc-15 in Pulmonary Arterial HypertensionTerminatedNCT00723554Phase 3Results posted
• Iloprost Power 15 in Pulmonary Arterial HypertensionCompletedNCT00709956Phase 3Results posted
• Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial HypertensionCompletedNCT00709098Phase 3Results posted
• Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial HypertensionCompletedNCT00667823Phase 3Results posted
• Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial HypertensionCompletedNCT00660179Phase 3Results posted
• Combination Therapy in Pulmonary Arterial HypertensionCompletedNCT00433329Phase 4Results posted
• BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompletedNCT00367770Phase 4Results posted
• Bosentan in Children With Pulmonary Arterial Hypertension Extension StudyCompletedNCT00319020Phase 3Results posted
• Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)CompletedNCT00303459Phase 4Results posted
• The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial HypertensionTerminatedNCT00302211Phase 3Results posted
• A Study of Macitentan in Children Below 2 Years of AgeWithdrawnNCT05731492Phase 1
• A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor AgonistCompletedNCT05427162Phase 1
• A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) ParticipantsTerminatedNCT04955990Phase 4
• A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or SelexipagCompletedNCT04567602
• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionActive, not recruitingNCT04273945Phase 3
• Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)Active, not recruitingNCT03838445Not applicable
• A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.CompletedNCT03422328Phase 3
• A Registry for Patients Taking UptraviCompletedNCT03278002
• Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United StatesCompletedNCT03197688
• Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)TerminatedNCT02968901Phase 4
• Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial HypertensionWithdrawnNCT02309463
• OPsumit USers RegistryCompletedNCT02126943
• Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAHCompletedNCT02112487Phase 3
• Adult Congenital Heart Disease Registry (QuERI)CompletedNCT01659411
• Eisenmenger Quality Enhancement Research InitiativeCompletedNCT01623492
• Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension ProgramCompletedNCT01389206
• Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)CompletedNCT00993408Phase 2
• Ventavis® Registry ProtocolTerminatedNCT00902603
• Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)TerminatedNCT00706082
• Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial HypertensionWithdrawnNCT00453414Phase 2
• Bosentan in Children With Pulmonary Arterial HypertensionCompletedNCT00319267Phase 3
• Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompletedNCT00317486Phase 4
• Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)TerminatedNCT00310830Phase 3
• Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class IICompletedNCT00091715Phase 3
• Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT00086463Phase 2